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Abstract: In Self-designing clinical trials, confidence intervals are derived for the differ-
ence and the ratio of normal means, where the results of the independent study stages are
combined using the weighted inverse normal method. The confidence intervals always hold
the predefined nominal confidence level. During the course of the Self-designing trial, the
sample sizes as well as the number of study stages can be determined simultaneously in a
completely adaptive way. Self-designing may be considered as the limit case of adaptive
group sequential designing of O’Brien and Fleming type when the full significance level is
shifted to the last stage. We consider the effect measures difference and ratio of normal
means, where the latter has not yet been considered in group sequential trials so far.
Concrete rules are derived for updating sample sizes and assigning weights to the stages
of the trial. The clinical trial may be originally designed either to show non-inferiority
or superiority. But, in each interim analysis, it is possible to change the planning from
showing non-inferiority to showing superiority or vice versa. The performance of the Self-
designing and the resulting confidence intervals are demonstrated in real-data examples
for both considered effect measures showing both kinds of switching during an ongoing
trial.
Keywords: Adaptive planning; Confidence interval; Learning rule; Ratio of means; Self-
designing; Switching between non-inferiority and superiority; Weighted inverse normal
method.
1 Introduction
In a clinical examination, the common effect measures for comparing a new agent to a
standard agent with regard to (at least) non-inferiority are the difference of means and the
ratio of means. Provided the standard agent is well known and stable in different popula-
tions, the suitable measure is the difference of means. Otherwise, the scale invariant ratio
1Address correspondence to Joachim Hartung, Department of Statistics, Dortmund University of
Technology, 44221 Dortmund, Germany; E-mail: hartung@statistik.tu-dortmund.de
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Figure 1: Examples of final 95%-confidence intervals for different study results.
of means is the preferred effect measure. In the analysis, the confidence interval approach
is of particular attractiveness, see e. g. EMEA (2000). From that guideline we also take
over the graphical illustration of switching from non-inferiority over to superiority, see
Figure 1.
The theoretical background for switching between non-inferiority and superiority is
discussed, for example, by Bauer and Kieser (1996) and Brannath et al. (2003). Practi-
cally this means that the position of the confidence interval determines the kind of result
of the study, independently of the question whether originally the study was planned as
non-inferiority or superiority trial.
In classical group sequential trials, the repeated confidence interval approach intro-
duced by Jennison and Turnbull (1984, 1989) may be applied for constructing confidence
intervals on the parameter of interest. For adaptive clinical trials, several proposals for
constructing a confidence interval exist for various kinds of flexible designs, see, for in-
stance, Lehmacher and Wassmer (1999), Liu and Chi (2001), Brannath, Posch, and Bauer
(2002), Brannath, Ko¨nig, and Bauer (2003), Frick (2002), Proschan, Liu, and Hunsberger
(2003), and Hartung and Knapp (2006).
In the following, we consider flexible adaptive group sequential trials in the sense that,
besides the adaptive choice of the sample sizes for the different stages, the number of
stages can be either fixed in advance or can be determined also in an adaptive way, the
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latter approach named Self-designing as introduced by Fisher (1998), Shen and Fisher
(1999).
In the Self-designing approach of group sequential trials, one decides adaptively after
each interim-analysis during the course of the study whether exactly one or at least two
further study stages will be performed by use of the unblinded results of all the already
conducted interim-analyses. The Self-designing trial ends when the (finite) variance of
an a priori fixed final test statistic is used up. Hartung (2001) derives Self-designing
rules where the weighted inverse normal method is used for combining the p-values of
the independent study stages. Simultaneously the weights and the sample sizes can be
chosen adaptively. Considering the adaptive extension of O’Brien and Fleming (1979)
designs, Self-designing can be viewed as the limit case when the needed level attained of
the last stage reaches the full overall significance level, see Hartung (2006). It should be
mentioned, that in spite of its practical importance, the effect measure ratio of means is
not considered in group sequential trials until now.
In a Self-designing trial, Cheng and Shen (2004) construct a confidence interval for
the mean difference of two normal variates, where the variance parameter is assumed
to be known. As in Shen and Fisher (1999), the sequence of possible sample sizes is
fixed in advance and just the weights assigned to the stages of the trial are really chosen
adaptively. For unknown variance, Cheng and Shen (2004) give an approximate solution.
Extending the proceeding of Hartung (2001, 2006) to the combination of parameterized
p-values, we will derive exact confidence intervals for both effect measures, difference
and ratio of normal means, with unknown variance parameter. Moreover, a confidence
interval for the variance parameter will also be derived. For both effect measures, suitably
combined learning rules provide an effective chance to choose both sample sizes and
weights simultaneously in an adaptive way. In our approach, we consider t-statistics
involving the unknown parameter and combine them using the weighted inverse normal
method from meta-analysis, see Hedges and Olkin (1985) or Hartung, Knapp, and Sinha
(2008). The confidence intervals are defined implicitly and, for the determination of the
boundaries, nonlinear equations have to be solved, whose solutions are unique.
In each interim analysis we may decide in the planning between non-inferiority and
superiority. Based on conditional error functions, we derive concrete rules for adaptive
designing, ranging from fixed prior information based planning over just updating of
variances up to completely data based planning. Our proceeding is a conditional power
approach, as applied at least implicitly, for instance, by Proschan and Hunsberger (1995),
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Denne (2001), Liu and Chi (2001), Proschan, Liu, and Hunsberger (2003) in two-stage
adaptive designs, and by Shen and Fisher (1999), Hartung (2000, 2001, 2006), Hartung
and Knapp (2003, 2006), Cheng and Shen (2004) in the context of Self-designing clinical
trials.
The outline of the paper is as follows. In Section 2, the basics for a Self-designing study
of comparing normal outcomes are summarized. The construction of a confidence interval
for the mean difference is described in Section 3. Section 4 contains the adaptive planning
for sample sizes and weights when the mean difference is the parameter of interest. More-
over, the switching of the planning between non-inferiority and superiority is addressed.
The construction of a confidence interval for the variance parameter is discussed in Sec-
tion 5, and in Section 6, an example is considered in which the methods presented so far
are illustrated. Section 7 contains the construction of a confidence interval when the ratio
of normal means is the parameter of interest. Moreover, some considerations of adaptive
planning in this situation are discussed. In Section 8, the methods of the previous section
are illustrated in an example. Finally, some concluding remarks are given, where also
point estimation of the considered effect measures is addressed.
2 Basic principles for a Self-designing study of com-
paring normal outcomes
Let xE and xC be independent normally distributed random variables with mean µE in an
experimental group E and mean µC in an (active) control group C with common variance
σ2 > 0, that is, succinctly
xE ∼ N (µE, σ2) and xC ∼ N (µC , σ2) . (1)
A comparative study is carried out consecutively in a number of, say k, independent
stages, denoted by stg(1), . . . , stg(k). In the i-th stage, i = 1, . . . , k, let us observe the
responses xEij, j = 1, . . . , nEi ≥ 2, and xCij, j = 1, . . . , nCi ≥ 2, where nEi and nCi are
the sample sizes in the respective groups. The observed mean difference measure in stg(i)
is
yi =
1
nEi
nEi∑
j=1
xEij − 1
nCi
nCi∑
j=1
xCij = x¯Ei − x¯Ci, i = 1, . . . , k. (2)
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The variance parameter σ2 is estimated in the i-th stage by the pooled estimator
s2i =
1
nEi + nCi − 2
(
nEi∑
j=1
(xEij − x¯Ei)2 +
nCi∑
j=1
(xCij − x¯Ci)2
)
, i = 1, . . . , k, (3)
which follows a scaled χ2-distribution with nEi + nCi − 2 degrees of freedom, that is,
(nEi + nCi − 2) s
2
i
σ2
∼ χ2(nEi + nCi − 2). (4)
The variance of yi is estimated in the i-th stage by
v̂ar(yi) =
(
1
nEi
+
1
nCi
)
s2i , (5)
and yi and s
2
i are stochastically independent, i = 1, . . . , k.
Let us assign a positive normed weight wi > 0 to each stage i, i = 1, . . . , k, with∑k
i=1wi = 1. Based on considerations in Fisher (1998), Shen and Fisher (1999), Hartung
(2001, 2006), and Cheng and Shen (2004), the sample sizes as well as the weights may
be chosen in a completely adaptive way. All the information of the unblinded data of
previous stages can be used to choose simultaneously the sample size and the weight for
the next stage. Let stg(0) denote a priori information and external restrictions, we express
the adaptive choice of sample sizes and weights as
ni = nˆ{i− 1} = nˆ{stg(0), stg(1), . . . , stg(i− 1)}, ni = nEi + nCi, (6)
and
wi = wˆ{i− 1} = wˆ{stg(0), stg(1), . . . , stg(i− 1)}, (7)
where wi ≤ 1− wΣ(i− 1), wΣ(i) =
∑i
j=1wi, wΣ(0) = 0, wΣ(k) = 1, wi > 0, i = 1, . . . , k.
Note that the number k of performed stages is random and will be realized during the
course of the sequential trial in dependence of the choice of weights. Of course, k has to be
finite (almost surely), and for practical reasons, k should be bounded by some reasonable
constant. Introducing a minimum weight, say wmin, 0 < wmin < 1, for a realized stage,
we obtain the boundary as k ≤ 1/wmin. A minimum sample size, say nmin, may also be
introduced, so that
ni ≥ nmin ≥ 4 and wi ≥ wmin > 0, i = 1, . . . , k. (8)
The use of minimum weight and minimum sample size leads to useful termination condi-
tions of the whole trial and can adjust some non-practicable suggestions of the (automatic)
learning rules for choosing ni and wi discussed in later sections.
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3 A confidence interval for the mean difference
With an a priori defined non-inferiority bound ∆0 ≥ 0, we are interested in testing
H0,∆ : µE ≤ µC −∆ versus H1,∆ : µE > µC −∆ , 0 ≤ ∆ ≤ ∆0, (9)
at a prescribed level α, 0 < α < 1/2. The alternative hypothesis H1,∆ means (∆−)non-
inferiority for 0 < ∆ ≤ ∆0, and, for ∆ = 0, superiority of E with regard to C.
Let ϑ = µE − µC denote the difference of means, which can be unbiasedly estimated
by yi in stg(i), i = 1, . . . , k, see (2). For the i-th stage, let us define the t-statistic
Ti(ϑ) =
yi − ϑ√
(1/nEi + 1/nCi) s2i
∼ t(nEi + nCi − 2) , (10)
that is, for the true parameter ϑ, the statistic Ti(ϑ) follows a (central) t-distribution with
nEi + nCi − 2 degrees of freedom.
Let Ft(ν) denote the cumulative distribution function of a t-variate with ν degrees of
freedom, then it holds, for the 1− p-value,
Ft(nEi+nCi−2)(Ti(ϑ)) ∼ U(0, 1), i = 1, . . . , k, (11)
where U(0, 1) stands for the uniform distribution in the unit interval. Then, we have
zi(ϑ) = Φ
−1[Ft(nEi+nCi−2)(Ti(ϑ))] ∼ N (0, 1) , i = 1, . . . , k, (12)
with Φ−1 the inverse of the standard normal distribution function Φ. Although sample
sizes and weights may be chosen adaptively as described in (6) and (7), the final combining
statistic follows a specified test distribution, that is,
Zk(ϑ) =
k∑
i=1
√
wi zi(ϑ) ∼ N (0, 1) , with wΣ(k) =
k∑
i=1
wi = 1, (13)
see Fisher (1998), Shen and Fisher (1999), and Hartung (2001).
The continuous distribution functions Ft(νi)(·) and the inverse distribution function
Φ−1(·) are (strictly) monotone increasing functions in their arguments. The pivotal statis-
tic Ti(ϑ) from (10) is monotone decreasing in ϑ, implying that Φ
−1(Ft(νi)(Ti(ϑ)) is mono-
tone decreasing in ϑ. Hence, the whole function Zk(ϑ) is monotone decreasing in ϑ.
So we can define the following confidence interval on ϑ,
CI(ϑ) =
{
d ∈ IR | Φ−1(α) ≤ Zk(d) ≤ Φ−1(1− α)
}
= [ ϑL , ϑU ] (14)
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where ϑL and ϑU are the unique solutions of the equations:
Zk(ϑL) = Φ
−1(1− α) and Zk(ϑU) = −Φ−1(1− α).
The confidence coefficient of CI(ϑ) is 1− 2α, 0 < α < 1/2. Since the solutions in (14) are
unique, they can easily be found iteratively using standard statistics software packages.
Let us now apply the confidence interval to the test problem (9). We decide, at level
α, for the alternative H1,∆, ∆ ∈ [0 , ∆0], if −∆ lies below CI(ϑ), and we do not reject
H0,∆0 , if CI(ϑ) covers −∆0, more succinctly, with ϑL from (14),
if −∆ < ϑL , then reject H0,∆,
if −∆0 ≥ ϑL , then stay with H0,∆0 .
(15)
Let us briefly consider the case that the variance parameter is known in advance, say
σ20. Then the statistic (10) becomes the z-statistic
Ti,0(ϑ) =
yi − ϑ√
1/nEi + 1/nCi σ0
=
yi − ϑ
σ(yi)
∼ N (0, 1). (16)
With zi(ϑ) = Φ
−1(Φ(Ti,0(ϑ))) = Ti,0(ϑ), Zk(ϑ) in (13) becomes Zk,0(ϑ) =
∑k
i=1
√
wiTi,0(ϑ) ∼
N (0, 1). Equating now Zk,0(ϑ) = ±Φ−1(1 − α) and solving for ϑ yields the (1 − 2α)-
confidence interval on ϑ
CI0(ϑ) =
[
k∑
i=1
√
wiyi/σ(yi)∑k
h=1
√
wh/σ(yh)
± Φ
−1(1− α)∑k
h=1
√
wh/σ(yh)
]
. (17)
This interval is also considered, in a different presentation, by Cheng and Shen (2004).
Replacing σ20 by the observed values s
2
i leads to approximate z-statistics in (16) and an
approximate confidence interval in (17). Note that the combined test statistics of Fisher
(1998) and Shen and Fisher (1999) are also special cases of the general weighted inverse
normal combining statistics, see Hartung (2006).
4 Adaptive planning for sample sizes and weights
The confidence interval CI(ϑ) in (14) results after k−1 interim analyses based on the un-
blinded data. In case an unexpected favorable parameter constellation has been observed
up to stage j and provided that wΣ(j) < 1, this may lead to considerations to switch
from showing non-inferiority to showing superiority, and so the trial is then continued
by further planning with ∆ = 0. Conversely, originally planned as a superiority trial, a
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first interim analysis may reveal that an unexpected large number of subjects would be
required. So, in case of an active control, one may decide to switch from showing supe-
riority to showing non-inferiority, and to reduce the sample size of the rest of the trial
by choosing some ∆ > 0 in the further planning. Note that also in this situation, a non-
inferiority bound ∆0 should have been defined at the beginning of the study, see also the
discussion in the guideline EMEA (2000). In the following, we present some learning rules
for choosing the sample sizes and the weights adaptively with the possibility of switching
in the planning between non-inferiority and superiority. Moreover, we chose two real-data
examples to demonstrate that both kinds of switching may occur during ongoing trials in
a quite natural way, see Sections 6 and 8.
For predefined type I and II error rates α, 0 < α < 1, and β, 0 < β < 1, respectively,
let us consider, for ease of presentation, the approximate normal sample size spending
function. Two steering parameters uj and vj will be introduced for each stage j in order
to cover a wide range of reasonable updating possibilities, whose realization would then
depend on a given concrete situation. We plan with equal sample sizes for both groups at
each stage. Based on information up to stage j, an estimate Aj(∆) > 0 of the standardized
mean difference (ϑ+∆)/σ may be assumed, where Aj(∆) is defined below. The power is
considered at the point ϑ + ∆ = σAj(∆) in the alternative H1,∆. For testing H0,∆ from
(9) by use of a t-test of level α at stage j + 1, a power of 1− β is approximately reached
when the total sample size for both groups at stage j + 1 is chosen as
fj(α, β,∆) =
4 [max{0 , Φ−1(1− α) + Φ−1(1− β)}]2
Aj(∆)2
, j = 0, 1, . . . , k, (18)
with
Aj(∆) = uj
j∑
i=1
n˜i∑j
h=1 n˜h
(
yi +∆
si
)
+ (1− uj) µE0 − µC0 +∆
vj s(j) + (1− vj) s0 > 0, ∆ ≥ 0,
s(j) =
(
j∑
i=1
ni − 2∑j
h=1 nh − 2j
s2i
)1/2
, n˜i =
2
1/nEi + 1/nCi
,
ni = nEi + nCi , 0 ≤ uj ≤ 1, u0 = 0, and 0 ≤ vj ≤ 1, v0 = 0
where µE0 − µC0 +∆ > 0 denotes a predefined value from the alternative H1,∆ at stg(0),
for instance, an a priori guess, and s20 > 0 a supposed value for σ
2. An unrealistic small
value in (18) may be replaced by some reasonable sample size, for instance, by nmin from
(8).
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Let us comment the role of the two steering parameters uj and vj, 0 ≤ uj ≤ 1 and
0 ≤ vj ≤ 1. By choosing uj = 0 and vj = 0, we get a purely prior information based
sample size plan with respect to the parameters. The choice uj = 0 and vj > 0 leads to
adaptive plans that only use updated variances, where s(j)2 is the pooled estimator of σ2
up to stg(j). Such kind of updating is used, for instance, in Denne and Jennison (2000)
and references cited therein. For uj = 1, involving n˜i, the harmonic mean of realized
sample sizes, the term Aj(∆) is a short-cut version of the meta-analytical combination
of standardized mean differences as discussed, for instance, in Hedges and Olkin (1985)
and Hartung and Knapp (2001). Putting uj = 0, when the first sample based estimate
in Aj(∆) is below the second one, gives priority to the second term as a lower bound.
The reverse choice of uj covers a situation considered in a two-stage-trial by Liu and
Chi (2001), and Proschan, Liu, and Hunsberger (2003), who also discuss the role of the
standardized mean difference in updating sample sizes.
Let us assume that up to stg(j − 1) we have determined sample sizes and weights
where wΣ(j − 1) < 1, by planning with ∆1, . . . ,∆j−1 ∈ [0,∆0] and at stg(j) we want to
plan with ∆j, that is, we have in mind to reject H0,∆j , ∆j ∈ [0,∆0], see (9). With the
realized sample sizes nEi and nCi , i = 1, . . . , j − 1, j ≥ 2, and defining Z0(−∆j) = 0, we
compute the combination statistic up to stg(j − 1), see (12),
Zj−1(−∆j) =
j−1∑
i=1
√
wi zi(−∆j) , j ≥ 1. (19)
Supposed we want to obtain a significant result at the next stage by assigning the full
remaining weight 1− wΣ(j − 1) to this stage. Then, by use of the projected p-value, say
pˆj,m, the following combination statistic
Zj,m(−∆j) = Zj−1(−∆j) +
√
1− wΣ(j − 1) Φ−1[1− pˆj,m], j ≥ 1, (20)
should attain the critical value Φ−1(1− α), that is,
pˆj,m = 1− Φ
[(
Φ−1(1− α)− Zj−1(−∆j)
) /√
1− wΣ(j − 1)
]
, j ≥ 1. (21)
This projected p-value is gained with the (conditional) power 1−β at ϑ+∆j = σAj−1(∆j) >
0 by choosing the sample size for the next stage j according to (18) as
mj = mj(β) = fj−1(pˆj,m, β,∆j), j ≥ 1. (22)
In the above procedure, the full weight is used up and stage j is the last one. In case
estimates of parameters involved in the trial may not have been stabilized yet, only a part
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of mj(β) should be used as sample size nj, that is nj = εj mj(β), with 0 < εj ≤ 1. The
remaining weight after stage (j − 1) is also divided proportionally to assign the weight
wj = εj (1− wΣ(j − 1)) at stage j, that is, summarized,
wj = εj (1− wΣ(j − 1)), nj = εj mj(β), nEj = nCj ≈ nj/2, j ≥ 1. (23)
The choice of wj means a proportional partition of the remaining variance of the final
N (0, 1)-test distribution.
Choosing a smaller power (1− βj), a possible choice of εj is provided by
εj = εj(βj) =
mj(βj)
mj(β)
, mj(βj) = fj−1(pˆj,m, βj,∆j), β ≤ βj < 1, j ≥ 1. (24)
Note that βj is only a lower bound of the type II error rate in stage j as long as wj <
1−wΣ(j−1). A similar basic idea is discussed by Hartung (2001) and applied in a 3-stage
Self-designing clinical trial with normal outcomes in Hartung (2006).
The pivotal element εj of steering the whole Self-designing process may also be defined
in a more direct way. From stage (j − 1) we have the p-value pj−1 = pj−1(−∆j−1) =
1 − Ft(nj−1−2)(Tj−1(−∆j−1)) based on nj−1 observations. Before realizing stage (j − 1),
upon the information up to stage (j − 2), we can compute the significance level αj−1,
which our test statistic should reach in stage (j − 1) with probability 1− β, that is,
αj−1 = x where x solves: nj−1 = fj−2(x, β,∆j−1), j ≥ 2. (25)
Comparing this expected value with the observed value, we come to new learning rules
for nj and wj by the following choice of the pivot εj as
εj = ε
∗
j = rRel
(
1− |αj−1 − pj−1|
αj−1 + pj−1
)
for j ≥ 2, (26)
where rRel denotes some relaxation factor, 0 < rRel ≤ 1.
In the extreme cases, when pj−1 tends to 1, whereas αj−1 is small, or when pj−1 tends
to 0, the pivot ε∗j comes near 0. This has the consequence, that nmin and wmin would
be taken for the next stage, see the detailed rules given below. A cautious choice of the
relaxation factor is rRel = 1/2, which even in the ideal case, when αj−1 = pj−1, suggests to
take only a half of the remaining weight 1−wΣ(j−1) and sample size mj(β), respectively,
for the following stage. For j = 1, we may choose ε∗1 as ε1(β1) from (24).
Incorporating the minimum sample size and minimum weight introduced in (8), we
can formulate the suitably combined learning rules for updating sample sizes and weights
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as follows: Assume that up to stage j − 1, j ≥ 1, there holds
ni ≥ nmin, wmin ≤ wi, i = 1, . . . , j − 1, and wΣ(j − 1) =
j−1∑
i=1
wi ≤ 1− wmin, (27)
and let εj be defined, for instance, by (24) or (26), then, using (22), calculate the weight
function
Wj = max
{
wmin , [1− wΣ(j − 1)] max
(
εj,
nmin
mj(β)
)}
, (28)
and set the weight wj and the sample size nj of the next stage j as follows:
wj =
{
Wj , if 1−Wj − wΣ(j − 1) ≥ wmin,
1− wΣ(j − 1) , otherwise, and put j = k,
(29)
and
nj = max
{
nmin ,
wj
1− wΣ(j − 1) mj(β)
}
. (30)
The choice of wj in (29) and nj in (30) guarantees the conditions in (27) for all stages and
thus, in particular, the upper boundary for the number of performed stages is 1/wmin.
Moreover, the full power 1− β is reached latest in stage j = k, conditioned on ϑ+∆k =
σAk−1(∆k) > 0.
5 A confidence interval on the variance parameter
Let Fχ2(ν) denote the distribution function of a χ
2-variate with ν degrees of freedom. With
the χ2-statistics from (4), we have in analogy to (11)
Fχ2(ni−2)
(
(ni − 2) s
2
i
σ2
)
∼ U(0, 1), ni = nEi + nCi, i = 1, . . . , k, (31)
leading to the combination statistic
ZVk (σ
2) =
k∑
i=1
√
wi Φ
−1
[
Fχ2(ni−2)
(
(ni − 2) s
2
i
σ2
)]
∼ N (0, 1),
k∑
i=1
wi = 1, (32)
which is monotone decreasing in σ2 > 0.
Often the predefined confidence level for the variance parameter is lower than the one
for the outcome measure. So, let us denote the confidence level for the variance by 1−2κ,
0 < κ < 1/2. With the unique solutions of the equations
ZVk (σ
2
L) = Φ
−1(1− κ) and ZVk (σ2U) = −Φ−1(1− κ),
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we build the (1− 2κ)-confidence interval
VCI(σ2) = [σ2L, σ
2
U ]. (33)
Since often descriptions of the standard deviation are preferable, we simply take the square
root of the boundaries in VCI and denote the resulting confidence interval on σ by VCI1/2.
6 An example for the effect measure difference of
means showing switching from non-inferiority to
superiority
Let us consider a clinical examination in which a new agent in an experimental group E
is compared to a control group C. The response variables are assumed as (essentially)
normally distributed. Let the parameter of interest ϑ be the difference of means, say
ϑ = µE−µC , and for both groups a common variance σ2 is assumed. In such a controlled
clinical trial concerning patients with acne papulopustulosa, Lehmacher and Wassmer
(1999) discuss an adaptive 3-stage group sequential test of Pocock (1977) type, which
led to an early stop for superiority of E with respect to C after the second stage at the
one-sided overall significance level of α = 0.005. The response variable is the reduction of
bacteria (after 6 weeks of treatment) from baseline, examined on agar plates and measured
as log CFU / cm2, CFU: colony forming units. We have taken over the parameter estimates
as presented in Table 1. The non-inferiority margin may be predefined as ∆0 = 0.1.
The test level is also chosen as α = 0.005 and the power as 1− β = 0.80. Each stage
is planned with equal sample sizes in both groups. Planning with ∆1 = 0.1 for showing
non-inferiority, we get the prior guess A0(∆1) = 0.9 using the prior guesses of ϑ and σ
from Table 1. With the critical value Φ−1(0.995) = 2.576, we obtain the total sample size
for a one-stage trial using (18),
m1 = f0(0.005, 0.2, 0.1) = 57.6.
Note that, for the superiority test with ∆ = 0, we would calculate the total sample size
as 73.
It was intended to start with a (1/3)m1, but by randomizing medications in blocks of
size 6, the first sample was chosen to have the size n1 = 24, that is, ε1 = n1/m1 = 0.4 = w1,
see (23). The trial starts and we obtain y1 = 1.549 and s1 = 1.316, leading to the small
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Table 1: Self-designing two-stage clinical trial concerning patients with acne papulopus-
tulosa: Data and confidence intervals on the treatment difference ϑ = µE − µC and on
the standard deviation σ.
Adaptive Adaptive Treatment Standard p-value
Stage sample size weight difference deviation pi(−∆)
0 — — 0.8 1.0 pi(−0.1) pi(0)
1 24
√
0.4 = 0.63 1.549 1.316 0.0028 0.0043
2 12
√
0.6 = 0.77 1.580 1.472 0.0381 0.0463
Confidence interval on
µE − µC σ
[ 0.231 , 2.894 ] [ 1.157 , 1.797 ]
Confidence level: 1− 2α = 0.99 Confidence level: 1− 2κ = 0.90
p-value p1(−0.1) = 0.0028. Consequently, we decide to switch in the planning over to
showing superiority. That means, we choose now ∆2 = 0.
At first we have to compute Z1(−∆2) =
√
0.4 Φ−1(1 − 0.0043) = 1.66 and then the
projected p-value, see (21),
pˆ2,m = 1− Φ[(2.576− 1.66)/
√
0.6] = 1− Φ[1.18],
leading to, see (22), with ∆2 = 0,
m2 =
4 [1.18 + 0.84]2
(1.549 / 1.316)2
= 11.7.
We put uj = 1 in (18) because the prior guesses turned out as too cautious. So it was
decided to finish the trial by assigning the full remaining weight to the second stage,
w2 = 0.6, and to choose the sample size n2 = 12.
By the results of the second stage, see Table 1, we obtain
Z2(0) = 0.63 · 2.63 + 0.77 · 1.68 = 2.95 > 2.576,
and equating Z2(ϑ) to 2.576 and to −2.576 gives the lower and upper bound, respectively,
of the 99%-confidence interval CI(ϑ), that is, CI(ϑ) = [0.231, 2.894], see also Figure 2 for
a graphical display.
For the confidence interval on the variance and the standard deviation, respectively,
we choose κ = 0.05 and obtain VCI(σ2) by equating
ZV2 (σ
2) =
√
0.4 Φ−1
[
Fχ2(22)
(
22 · 1.316
2
σ2
)]
+
√
0.6 Φ−1
[
Fχ2(10)
(
10 · 1.472
2
σ2
)]
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Figure 2: Construction principle of the final 99%-confidence interval for the difference of
means µE − µC in the real-data example from Section 6.
to±1.645. The solutions are VCI(σ2) = [1.339, 3.228] so that the resulting 90%-confidence
interval on σ is given as VCI1/2(σ) = [1.157, 1.797].
7 A confidence interval for the ratio of means and
adaptive planning
Let us assume that the independent random variables xE and xC , introduced in Section 2,
have positive means, µE > 0 and µC > 0. The same should hold for the observed means,
x¯Ei > 0 , x¯Ci > 0 , i = 1, . . . , k. The parameter of interest considered now is the ratio of
means,
λ =
µE
µC
, 0 < λ <∞.
Let ∆0 ≥ 0 be again a non-inferiority margin, we test
Hr0,∆ : λ ≤ 1−∆ versus Hr1,∆ : λ > 1−∆, 0 ≤ ∆ ≤ ∆0, ∆0 < 1, (34)
at a given level α, 0 < α < 1/2, where Hr1,∆ means superiority when ∆ = 0, otherwise
(∆−)non-inferiority of E with regard to C.
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Following an idea of Fieller (1940), see also Finney (1964), let us introduce the statistics
x¯i(λ) = x¯Ei − λ x¯Ci ∼ N
(
0 ,
(
1
nEi
+
λ2
nCi
)
σ2
)
, i = 1, . . . , k, (35)
and the t-statistics for i = 1, . . . , k,
T ri (λ) =
x¯i(λ)
σˆ(x¯i(λ))
=
x¯Ei − λ x¯Ci√
(1/nEi + λ2/nCi) s2i
∼ t(ni − 2), ni = nEi + nCi, (36)
where s2i is the pooled variance estimator from (3).
Suppressing the subscript i and putting Q = ((1/nE + λ
2/nC) s
2)1/2, we get the
derivative
d
dλ
T r(λ) =
− x¯C Q− (x¯E − λ x¯C)Q−1 s2 λ/nC
Q2
=
− x¯C Q2 − (x¯E − λ x¯C) s2 λ/nC
Q3
=
− (x¯C/nE + λ x¯E/nC) s2
Q3
< 0, for λ > 0.
Hence T r(λ) is monotone decreasing for positive λ. So, we obtain the final weighted
inverse normal combination statistic
Zrk(λ) =
k∑
i=1
√
wi Φ
−1 [Ft(ni−2)(T ri (λ))] ∼ N (0, 1), wΣ(k) = 1 , (37)
which is monotone decreasing in λ, λ > 0.
Defining
T ri (∞) =
−x¯Ci√
s2i /nCi
= lim
λ→∞
T ri (λ) and T
r
i (0) =
x¯Ei√
s2i /nEi
, i = 1, . . . , k, (38)
and herewith Zrk(∞), Zrk(0), we have the following boundaries for Zrk(λ),
Zrk(∞) = inf
λ>0
Zrk(λ) < Z
r
k(λ) < sup
λ>0
Zrk(λ) = Z
r
j (0), 0 < λ <∞. (39)
In analogy to (14), we can formulate the confidence interval on λ as follows,
CIr(λ) = [λL , λU ] , (40)
where λL solves Z
r
k(λL) = Φ
−1(1− α) if Zrk(0) > Φ−1(1− α), otherwise set λL = 0,
and λU solves Z
r
k(λU) = −Φ−1(1 − α) if Zrk(∞) < −Φ−1(1 − α), otherwise set λU = ∞.
The unique solutions of (40) can again easily be found iteratively by standard statistics
software packages. The confidence coefficient of CIr(λ) is 1− 2α.
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For w1 = 1 = k, solving the equations implied by (40) explicitly, we get a formal
representation of Fieller‘s well-known confidence interval for the ratio of means, see Fieller
(1940), Finney (1964).
In the test problem (34), we proceed as follows at level α, 0 < α < 1/2:
if 1−∆ < λL, then reject Hr0,∆,
if 1−∆0 ≥ λL, then stay with Hr0,∆0 .
(41)
In the following, we present some considerations on learning rules for adaptively chosen
samples sizes and weights in the present context. Planning with equal sample sizes in the
two groups and suppressing the subscript i, we set nE = nC = M , ξ = µE − (1 −∆)µC
for a fixed ∆ ∈ [0 , ∆0], and x = xE − (1−∆)xC . Then
x ∼ N (ξ, σ(x)2) and x¯ ∼ N (ξ, 1
M
σ(x)2
)
, (42)
where σ(x)2 = (1 + (1−∆)2)σ2.
For given type I and II error rates α and β, respectively, testing the point hypotheses
H∗0 : ξ = 0 versus H
∗
1 : ξ = ξ
∗ > 0
by
T r0 (1−∆) =
√
M
x¯
σ(x)
∼ N (0, 1) under H∗0, (43)
the required sample size M has to be chosen (one-sample formula) as follows,
M =
[max{0 , Φ−1(1− α) + Φ−1(1− β)}]2
(ξ∗/σ(x))2
. (44)
At stg(0), let s20 > 0 be an assumed value for σ
2 and ξ∗ = µE0 − (1 − ∆)µC0 > 0 be
a chosen value in the alternative Hr1,∆, then the sample size n = 2M for both groups is
obtained by the sample size spending function g0(α, β,∆) defined by
g0(α, β,∆) = 2
[max{0 , Φ−1(1− α) + Φ−1(1− β)}]2
B0(∆)2
, (45)
where
B0(∆) =
µE0 − (1−∆) µC0
s0
√
1 + (1−∆)2 > 0.
Instead of the normal test statistic T r0 (λ) from (43), the t-statistic T
r
i (λ) from (36) is
used at the i-th stage of the trial and so g0(α, β,∆) delivers approximate, lower values
for the desired sample sizes. For ease of presentation, we further consider only a purely
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sample based updating, say by gj(·, β,∆), j ≥ 1, and a mixture between g0 for exclusively
prior information based sample size planning, and gj, j ≥ 1, can be arranged in the
same kind as demonstrated in Section 4, see (18). We estimate the standardized mean
difference, under the alternative Hr1,∆, in the denominator of (44) at stage j by combining
the estimates of stg(1) up to stg(j) weighted by the harmonic means of the realized sample
sizes in the stages. We obtain
gj(α, β,∆) = 2
[max{0 , Φ−1(1− α) + Φ−1(1− β)}]2
Bj(∆)2
, j = 1, . . . , k, (46)
where
Bj(∆) =
j∑
i=1
n˜i∑j
h=1 n˜h
x¯Ei − (1−∆)x¯Ci
si
√
1 + (1−∆)2 > 0 , n˜i =
2
1/nEi + 1/nCi
.
If Bj is not positive, gj may be replaced by a part of g0, or the trial is not continued with
the specified non-inferiority margin ∆ in mind. An unrealistic small value in (45) or (46)
may be replaced, for instance, by nmin from (8).
The test statistic for (34) is Zrk(1−∆), see (37). Assume that up to stg(j−1) we have
gained Zri (λ) =
∑i
h=1
√
wh z
r
h(λ), with z
r
h(λ) = Φ
−1 [Ft(nh−2) (T rh(λ))]. Then, in analogy
to (21), we derive the projected p-value for stg(j) as
pˆrj,m = 1− Φ
[(
Φ−1(1− α)− Zrj−1(1−∆)
) /√
(1− wΣ(j − 1))
]
, j ≥ 1, (47)
which as in (22), (23) yields the needed sample size and weight for stg(j) as, see (45),
(46),
nj = εj m
r
j(β) and wj = εj (1− wΣ(j − 1)), 0 < εj ≤ 1, (48)
where mrj = m
r
j(β) = gj−1(pˆ
r
j,m, β,∆), nEj = nCj ≈ nj/2, j = 1, . . . , k. The power is
conditioned on µE − (1 − ∆)µC = Bj−1(∆)σ
√
1 + (1−∆)2 > 0. The pivotal learning
element εj can be chosen in an analogue manner as in (24) and (26). Taking into account
a minimum weight and sample size at each stage, see (8), the suitably combined learning
rules of (29) for updating sample sizes and weights can be carried over.
8 An example for the ratio of means showing switch-
ing from superiority to non-inferiority
Let us consider a clinical trial, one of the authors was concerned with as a biometrical
advisor. A new (E) and a standard drug (C), two different inhalers, for treating patients
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Table 2: Self-designing clinical trial treating patients with asthma bronchiale for the
effect measure ratio of means λ concerning a lungs functioning parameter (FEV1): Data,
confidence interval on λ with confidence coefficient 0.95, and combined test statistics.
Sample Data (in `) Confidence interval Combined
Stage size Weight on on test
i ni
√
wi µE µC σ λ = µE/µC statistics
0 — — 2.75 2.50 0.75 1−∆0 = 0.90 Zri (1.0) Zri (0.9)
1 128
√
1/3 2.67 2.55 0.81 0.482 1.563
2 56
√
2/3 2.70 2.56 0.87 [ 0.951 , 1.162] 0.971 2.997
with asthma bronchiale are compared with respect to a lung function parameter named
FEV1: forced expiratory volume in 1 second, measured in liter (`). The ratio of means
is the common outcome measure in that application. A nearly normed non-inferiority
margin for the clinical parameter is ∆0 = 10%. The type I and II error rates of the trial
are chosen as α = 0.025 and β = 0.10, respectively. The two treatment groups are equally
sized at each stage and the drugs are equally randomized within blocks of size 8. The
investigators were optimistic so that the trial starts with an attempt to show superiority
(∆ = 0). The first weight is scheduled as w1 = 1/3 or ε1 = 1/3.
The critical value is 1.96 and, with the assumed prior information from Table 2, we
compute by (45) for a one-stage trial 378 patients to be observed (with ∆ = 0). Using (48)
we obtain n1 = 126 and choose n1 = 128 because of the randomization scheme. With the
observed data, see Table 2, we obtain Zr1(1) = 0.48. We recognize that the prior guesses
of the parameters were too optimistic for that study population with respect to the new
drug. So we use in the planning for the next stage only the observed values of stg(1),
especially as they are based on a relatively large number of patients. So, with ∆ = 0,
we get pˆr2,m = 0.035, B1(0) = 0.105, and, for m
r
2 with ∆ = 0, we calculate a number of
1736 patients to be observed at the next stages for the chance of showing superiority. So
the decision was made to stay with showing non-inferiority being sufficient for regulatory
concerns.
Planning with ∆ = ∆0 = 0.10, we compute Z
r
1(0.90) = 1.56, pˆ
r
2,m = 0.31, B1(0.10) =
0.344 and by (46) for the total size of the remaining stages mr2 = 53. It was decided to
finish the trial after the second stage, so the final sample size is n2 = 56 because of the
randomization scheme. The combination statistic is Zr2(λ) =
√
1/3 zr1(λ) +
√
2/3 zr2(λ),
see (37). Equating Zr2(λ) to ±1.96 and solving for λ leads to the confidence interval,
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CIr(λ) = [0.951 , 1.162], on the ratio λ, which lies clearly above 0.90. Further, with
zr2(0.90) = 1.76, we calculate the final test value, Z
r
2(0.90) = 0.58 · 2.70 + 0.82 · 1.76 =
3.01 > 1.96, confirming significant non-inferiority.
9 Final remarks
Confidence intervals on the effect measures difference and ratio of means are derived by
combining parameterized t-statistics via the weighted inverse normal method. Assigning
consecutively different weights to the stages, the number of stages is determined during the
ongoing trial. Suitably combined learning rules are derived for simultaneously updating
sample sizes and weights. The consequence is an effective controlling of the clinical trial,
see also Fisher (1998) for general considerations in that direction.
The impression may arise that Self-designing concepts are a matter more for longer
running studies with many interim analyses. But let us consider a situation where, based
on the available a priori information, a two-stage trial seems to be appropriate. Usually
no surprising positive results are expected in the interim analysis, so that in the most
practical applications, an O’Brien and Fleming (1979) design is chosen, that provides a
greater chance for showing significance at the end of the study than, for instance, the
Pocock (1977) design. However, there is practically no chance to show significance in the
interim analysis. For example, an one-sided O’Brien and Fleming test at overall level
α = 0.025 needs for significance a level attained at the end of the study of 0.024, but
of 0.0026 in the interim analysis. So in that situation, a better choice would be a Self-
designing concept, where the weight for the first stage can be set to 1/2 as in the usual
2-stage O’Brien and Fleming design. Then the full level α is preserved at the end of the
study, but we have the additional option to decide in the interim analysis for at least one
further interim analysis if the observed treatment effects will not satisfy the expectations.
Choosing in advance a 3-stage O’Brien and Fleming design, is not a good idea in the
considered situation, because then, even in the second stage, a low level attained of only
0.007 would be needed for showing significance. So nearly surely, a third stage could not
be avoided. For comparison, the corresponding Pocock design needs a level attained of
0.011 at each of the three planned stages, whereas the Self-designing concept needs just
the full level of 0.025 to be attained at the end of the study after one or more interim
analyses.
Consequently, a Self-designing concept can be a reasonable alternative to classical
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group sequential trials, see also the simulation results reported in Hartung (2006), and
the real-data examples in Section 6 and 8. Moreover, Self-designing can be considered as
the limit case of O’Brien and Fleming designing, when the needed level attained assigned
to the last stage of the trial tends to the full overall significance level, as discussed by
Hartung (2006). That corresponds, in the Wang and Tsiatis (1987) δ-class of group
sequential trials, to the limit case when the design parameter δ tends to −∞. In a non-
adaptive setting, this makes less sense. But in an adaptive approach, interim analyses are
used not only for considering safety concerns of the clinical trial but also for the chance
to reassess the sample size planning, and being not less important, the number of possible
interim analyses has not to be specified in advance anymore.
Besides all these considerations, in spite of its vital practical importance, the effect
measure ratio of means, with the variances of the outcomes assumed to be known or not,
seems not to be considered as well in classical group sequential trials as in their adap-
tive extensions until now, neither for testing non-inferiority nor for deriving confidence
intervals.
Sample sizes n are computed in Sections 4 and 7 through a normal approximation
for applying a t(n − 2)-variate. Nearly exact values are achieved by correcting with the
variance of a t(n−2)-variate, that is, replacing n by ncorr = n(n−2)/(n−4), n ≥ 5, being
relevant for small values of n. The idea behind is the same as in replacing a t-variate by
a normal variate with identical variance. However, computed values usually have to be
modified to take into account the particular randomization scheme applied in a clinical
trial.
Unlike the inverse chi-square (χ2) combination method considered, for instance, by
Bauer and Ko¨hne (1994), Liu and Chi (2001), and Frick (2002) in two-stage designs
and by Hartung (2000) and Hartung and Knapp (2003, 2006) for Self-designing trials,
the inverse normal combination method is symmetric in the sense that positive values of
the t-statistics are accumulated in the same way as negative values. So no direction of
deviations from the null-distribution is preferred, see also Hedges and Olkin (1985, p. 40).
Even when sample sizes and weights of the stages are identical, the results by applying
both combination methods to the same data may differ. For instance, in the real-data
example of Self-designing discussed in Hartung (2006, p. 523), combining by use of the
inverse normal method yields a global p-value (0.0027) that is less than a half of the global
p-value (0.0057) reached by applying the inverse χ2 method to the same observed data
of the three stages when testing for superiority. This tendency is in concordance with
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simulation results which assign a higher mean sample size to the inverse χ2-method in
order to reach the same p-values as the inverse normal method, see Hartung (2006).
Finally let us briefly address point estimation. The combination statistic Zk(ϑ) from
Section 3 is N (0, 1)-distributed with mode and median 0. A maximum likelihood (ML)
estimator ϑˆML of the difference ϑ = µE − µC is given as the solution of Zk(ϑˆML) =
0. Sometimes, such an estimator is also called pseudo ML-estimator. The global p-
value is pG(ϑ) = 1 − Φ(Zk(ϑ)), and solving the equation pG(ϑ) = 1/2 yields ϑˆML as
solution. Hence, noting that Zk(ϑ) is monotone in ϑ, ϑˆML is median unbiased, cf. Cox
and Hinkley (1974, p. 273), Liu and Chi (2001). That means, the ML-estimator lies with
equal probability below and above the parameter ϑ. For large sample sizes ni, ϑˆML is
approximated by
ϑˆAML =
k∑
i=1
[
yi
√
wi/σˆ(yi)
]/[ k∑
h=1
√
wh/σˆ(yh)
]
,
see (16) and (17), which uses the inverse estimated standard errors instead of the in-
verse estimated variances of the yi’s as known from meta-analysis, see Hartung, Knapp,
and Sinha (2008). Weighted means like ϑˆAML are used in the generalized Cochran-Wald
statistics considered by Hartung, Bo¨ckenhoff, and Knapp (2003).
Using ZVk (σ
2) from Section 5 yields the median unbiased ML-estimator σˆ2ML of σ
2
by solving ZVk (σˆ
2
ML) = 0, and via Z
r
k(λ) from Section 7, we get the median unbiased
ML-estimator λˆML of the ratio λ = µE/µC as the solution of Z
r
k(λˆML) = 0.
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